July 3, 2017
Measure Summaries
American Academy of Dermatology
American Medical Association
- Oncology: percentage of female patients aged 18 years and older with Stage I (T1b) through IIIC, estrogen receptor (ER) or progesterone receptor (PR) positive breast cancer who were prescribed tamoxifen or aromatase inhibitor (AI) during the 12-month reporting period. This updates a previously published measure summary.
- Oncology: percentage of patient visits, regardless of patient age, with a diagnosis of cancer currently receiving chemotherapy or radiation therapy in which pain intensity is quantified. This updates a previously published measure summary.
- Oncology: percentage of patients aged 18 through 80 years with American Joint Committee on Cancer (AJCC) Stage III colon cancer who are referred for adjuvant chemotherapy, prescribed adjuvant chemotherapy, or have previously received adjuvant chemotherapy within the 12-month reporting period. This updates a previously published measure summary.
- Prostate cancer: percentage of patients, regardless of age, with a diagnosis of prostate cancer at low (or very low) risk of recurrence receiving interstitial prostate brachytherapy, OR external beam radiotherapy to the prostate, OR radical prostatectomy, OR cryotherapy who did not have a bone scan performed at any time since diagnosis of prostate cancer. This updates a previously published measure summary.
NHS Scotland
- Breast cancer: proportion of patients undergoing wide excision and/or an axillary sampling procedure for breast cancer as day case surgery.
- Breast cancer: proportion of patients with breast cancer (invasive or ductal carcinoma in-situ) having breast conservation surgery with final radial excision margins of less than 1 mm.
- Breast cancer: proportion of patients with breast cancer (invasive or in-situ) having breast conservation surgery who undergo re-excision or mastectomy following initial breast surgery.
- Breast cancer: proportion of patients with breast cancer having conservation surgery who receive radiotherapy to the breast.
- Breast cancer: proportion of patients with breast cancer under 30 years of age referred to a specialist clinic for genetic testing.
- Breast cancer: proportion of patients with breast cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
- Breast cancer: proportion of patients with breast cancer who are enrolled in an interventional clinical trial or translational research.
- Breast cancer: proportion of patients with breast cancer who die within 30 days of chemotherapy treatment.
- Breast cancer: proportion of patients with breast cancer who undergo immediate breast reconstruction at the time of mastectomy.
- Breast cancer: proportion of patients with invasive breast cancer for whom the HER2 status (as detected by immunohistochemistry [IHC] and/or fluorescence in-situ hybridization [FISH] analysis) is reported within 2 weeks of core biopsy.
- Breast cancer: proportion of patients with invasive breast cancer who have a greater than or equal to 5% overall survival benefit of chemotherapy treatment predicted at 10 years that undergo adjuvant chemotherapy.
- Breast cancer: proportion of patients with invasive breast cancer who undergo assessment of the axilla by ultrasound before surgery.
- Breast cancer: proportion of patients with invasive breast cancer with suspicious morphology reported on ultrasound who undergo a fine-needle aspiration (FNA)/core biopsy of the axilla before surgery.
- Breast cancer: proportion of patients with invasive or in-situ breast cancer who have a non-operative diagnosis (core biopsy/large volume biopsy).
- Breast cancer: proportion of patients with triple negative breast cancer under 40 years of age referred to a specialist clinic for genetic testing.
- Breast cancer: proportion of surgically treated patients with breast cancer less than 20 mm whole tumour size on histology (invasive plus in-situ disease) treated by breast conservation surgery.
- Hepatopancreatobiliary (HPB) cancer: number of surgical resections for pancreatic, duodenal, or distal biliary tract cancer performed by each surgeon/centre in a given year.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients undergoing resection for pancreatic cancer who receive adjuvant chemotherapy.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients who undergo resection for pancreatic, duodenal, or distal biliary tract cancer.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) not undergoing treatment with curative intent (liver transplantation, resection or ablative therapies) who receive trans-arterial chemoembolisation (TACE) or approved systemic anti-cancer therapy (SACT).
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment (liver transplant, resection, ablation, trans-arterial chemoembolisation [TACE] or systemic anti-cancer therapy [SACT]) who die within 30 days of definitive treatment.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing disease specific treatment with curative intent (liver transplant, resection, or ablation) who die within 90 days of definitive treatment.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) undergoing either CT or MRI and with full information recorded.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with hepatocellular carcinoma (HCC) who meet the current UK listing criteria for liver transplantation who are referred to the Scottish Liver Transplant Unit (SLTU).
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with HPB cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or biliary tract cancer who undergo CT of the chest, abdomen and pelvis.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal or distal biliary tract cancer undergoing non-surgical treatment who have a histological or cytological diagnosis.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal, or distal biliary tract cancer undergoing surgical resection who die within 30 and 90 days.
- Hepatopancreatobiliary (HPB) cancer: proportion of patients with pancreatic, duodenal, or distal biliary tract cancer who undergo pancreatoduodenectomy where greater than or equal to 15 lymph nodes are resected and pathologically examined.
- Prostate cancer: number of radical prostatectomy procedures performed by a surgeon over a 1 year period.
- Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy and docetaxel chemotherapy.
- Prostate cancer: proportion of patients presenting with metastatic prostate cancer (TanyNanyM1) treated with immediate hormone therapy.
- Prostate cancer: proportion of patients with high risk prostate cancer undergoing radical treatment who have MRI of the prostate and isotope bone scan (or alternative whole body MRI evaluation).
- Prostate cancer: proportion of patients with intermediate risk prostate cancer undergoing radical treatment who have MRI of the prostate.
- Prostate cancer: proportion of patients with metastatic prostate cancer (TanyNanyM1) discussed at the multidisciplinary team (MDT) meeting within 4 weeks of commencing treatment.
- Prostate cancer: proportion of patients with non-metastatic prostate cancer (TanyNanyM0) discussed at the multidisciplinary team (MDT) meeting before definitive treatment.
- Prostate cancer: proportion of patients with pathologically confirmed, organ confined (stage pT2) prostate cancer who undergo radical prostatectomy in which tumour is present at the margin (i.e., positive surgical margin).
- Prostate cancer: proportion of patients with prostate adenocarcinoma who undergo prostate needle biopsy where the pathology report contains a full set of data items.
- Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo multiparametric MRI within 6 months of diagnosis.
- Prostate cancer: proportion of patients with prostate cancer under active surveillance who undergo trans-rectal ultrasound guided (TRUS) prostate re-biopsy within 14 months of diagnosis.
- Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 0 pads per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.
- Prostate cancer: proportion of patients with prostate cancer undergoing radical prostatectomy with post surgical incontinence (greater than 1 pad per day measured using a validated tool) at 1 year (10 to 14 months) post radical prostatectomy.
- Prostate cancer: proportion of patients with prostate cancer who are enrolled in an interventional clinical trial or translational research.
- Prostate cancer: proportion of patients with prostate cancer who die within 30 days of chemotherapy.
- Prostate cancer: proportion of patients with prostate cancer who undergo trans-rectal ultrasound guided (TRUS) biopsy of the prostate where a minimum of 10 cores are received by pathology.
|
Announcements
Expert Commentaries
View expert insight on current issues of importance to the measure and/or guideline field.
Coming Soon
New NHS Scotland Cancer Quality Performance Indicators (QPIs) on Cutaneous Melanoma, Lung Cancer, and Lymphoma.
Health Awareness Topics: July 2017
International Group B Strep Awareness Month (see related measures)
How to Participate
Submit Measures: Visit our Submit Measures page for information on how to submit your organization's measures.
Suggest a Measure for Possible Inclusion: Submit your suggestions for evidence-based quality measures and measure sets that you would like to see included in NQMC.
NQMC Sister Resource
Look for evidence-based clinical practice guidelines in AHRQ's National Guideline Clearinghouse (NGC).
Email Updates
How satisfied are you with this e-mail bulletin? Give Us Your Feedback